{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:47:18Z","timestamp":1789958838899,"version":"4.0.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University of Saudi Arabia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0168947","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T21:45:48Z","timestamp":1483998348000},"page":"e0168947","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":9,"title":["Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia"],"prefix":"10.1371","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-4878","authenticated-orcid":true,"given":"Haneen","family":"Banjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damith","family":"Ranasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Adelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trent","family":"Kroger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naeem","family":"Chaudhri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,3]]},"reference":[{"key":"ref1","first-page":"1018","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"JF Apperley","year":"2007","journal-title":"Oncology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11899-009-0009-2","article-title":"Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy","volume":"4","author":"DL White","year":"2009","journal-title":"Current Hematologic Malignancy Reports"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"J Cortes","year":"2012","journal-title":"Blood"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"M Baccarani","year":"2006","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR\u2013ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"T Hughes","year":"2006","journal-title":"Blood"},{"issue":"6","key":"ref6","first-page":"872","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"M Baccarani","year":"2013"},{"key":"ref7","first-page":"59","article-title":"Applications of Machine Learning in Cancer Prediction and Prognosis","volume":"2","author":"JA Cruz","year":"2006","journal-title":"Cancer Informatics"},{"key":"ref8","first-page":"9","article-title":"Prognostic versus predictive value of biomarkers in oncology","volume":"44","author":"CNAM Oldenhuis","year":"2008","journal-title":"European Journal of Cancer"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s11912-010-0116-1","article-title":"Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: What Is the \u201cBest\u201d Therapy?","volume":"12","author":"M Agrawal","year":"2010","journal-title":"Current oncology reports (1523\u20133790)"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11899-011-0087-9","article-title":"Predicting the response of CML patients to tyrosine kinase inhibitor therapy","volume":"6","author":"DL White","year":"2011","journal-title":"Current Hematologic Malignancy Reports"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1182\/blood-2010-11-317123","article-title":"Predicting response in CML","volume":"117","author":"F Guilhot","year":"2011","journal-title":"Blood"},{"key":"ref12","first-page":"822","article-title":"Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure","volume":"117","author":"E Jabbour","year":"2010","journal-title":"Blood"},{"issue":"22","key":"ref13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V114.22.507.507","article-title":"The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial","volume":"114","author":"DL White","year":"2009","journal-title":"Blood [0006\u20134971]"},{"issue":"11","key":"ref14","first-page":"405","article-title":"The IC50 Assay Is Predictive of Molecular Response, and Indicative of Optimal Dose in De-Novo CML Patients","volume":"112","author":"D White","year":"2008","journal-title":"Blood [0006\u20134971]"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in &quot;good-risk&quot; chronic granulocytic leukemia","volume":"63","author":"J Sokal","year":"1984","journal-title":"Blood"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa","volume":"90","author":"J Hasford","year":"1998","journal-title":"Jornal of the National Cancer Institute"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"J Hasford","year":"2011","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1\u2212mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"DL White","year":"2006","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"DL White","year":"2007","journal-title":"Blood"},{"issue":"5","key":"ref20","article-title":"Relationship of the BCR gene breakpoint and the type of BCR\/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia","volume":"8","author":"W Prejzner","year":"2002","journal-title":"Medical science"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"D Verma","year":"2009","journal-title":"Blood (0006\u20134971)"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1182\/blood-2011-10-388967","article-title":"EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience","volume":"119","author":"E Jabbour","year":"2012","journal-title":"Blood"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"S Branford","year":"2013","journal-title":"Blood"},{"issue":"54","key":"ref24","article-title":"Biomarkers for determining the prognosis in chronic myelogenous leukemia","volume":"6","author":"K Sweet","year":"2013","journal-title":"Journal of Hematology & Oncology"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets2015 2015-02-05 00:00:00. 915\u201323 p.","DOI":"10.1182\/blood-2014-07-590315"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1177\/0962280206074466","article-title":"A comparison of imputation techniques for handling missing predictor values in a risk model with a binary outcome","volume":"16","author":"G Ambler","year":"2007","journal-title":"Stat Methods Med Res"},{"key":"ref27","first-page":"639","article-title":"Classification, Clustering, and Data Mining Applications. Studies in Classification, Data Analysis, and Knowledge Organisation","author":"E Acuna","year":"2004"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.artmed.2013.01.003","article-title":"Missing data in medical databases: Impute, delete or classify?","volume":"58","author":"F Cismondia","year":"2013","journal-title":"Artificial Intelligence in Medicine"},{"key":"ref29","unstructured":"Starkweather J, Herrington R. Replace Missing Values. Secondary Replace Missing Values 2014. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.unt.edu\/rss\/class\/Jon\/SPSS_SC\/Module6\/SPSS_M6_1.htm\" xlink:type=\"simple\">http:\/\/www.unt.edu\/rss\/class\/Jon\/SPSS_SC\/Module6\/SPSS_M6_1.htm<\/ext-link>."},{"key":"ref30","unstructured":"Thamas D. CBE What the White Cell. IMVS Newsletter. 2007."},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1145\/2594473.2594475","article-title":"Comprehensible classification models: a position paper","volume":"15","author":"AA Freitas","year":"2013","journal-title":"ACM SIGKDD Explorations"},{"key":"ref32","article-title":"Machine learning","author":"T Mitchell","year":"1997"},{"key":"ref33","article-title":"Classification and regression trees","author":"L Breiman","year":"1984"},{"key":"ref34","author":"R Timofeev","year":"2004"},{"key":"ref35","unstructured":"Quinlan JR, editor Generating production rules from decision trees. Proceeding IJCAI&apos;87 Proceedings of the 10th international joint conference on Artificial intelligence; 1987; USA: Morgan Kaufmann Publishers Inc."},{"issue":"8","key":"ref36","article-title":"Improving the accuracy of decision tree induction by feature preselection Applied Artificial Intelligence: An International Journal","volume":"15","author":"P Perner","year":"2001"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Prati RC, editor Combining feature ranking algorithms through rank aggregation. Neural Networks (IJCNN), The 2012 International Joint Conference on; 2012 10\u201315 June 2012.","DOI":"10.1109\/IJCNN.2012.6252467"},{"key":"ref38","first-page":"127","article-title":"Modern Clinical Trial Analysis","author":"M Qian","year":"2013"},{"key":"ref39","unstructured":"Cheng T-H, Wei C-P, Tseng VS, editors. Feature Selection for Medical Data Mining: Comparisons of Expert Judgment and Automatic Approaches. Proceedings of the 19th IEEE Symposium on Computer-Based Medical Systems (CBMS&apos;06); 2006: IEEE Computer Society."},{"issue":"7","key":"ref40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5120\/169-295","article-title":"Feature Subset Selection Problem using Wrapper Approach in Supervised Learning","volume":"1","author":"AG Karegowda","year":"2010","journal-title":"International Journal of Computer Applications"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Lasserre J, Arnold S, Vingron M, Reinke P, Hinrichs C. Predicting the outcome of renal transplantation2012 2012-03-01 00:00:00. 255\u201362 p.","DOI":"10.1136\/amiajnl-2010-000004"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2105-7-91","article-title":"Bias in error estimation when using cross-validation for model selection","volume":"7","author":"S Varma","year":"2006","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"ref43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/gtmb.2009.0126","article-title":"Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia","volume":"14","author":"SH Khalil","year":"2010","journal-title":"Genetic testing and molecular biomarkers"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/bmt.2013.146","article-title":"Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT","volume":"49","author":"R Shouval","year":"2014","journal-title":"Bone marrow transplantation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0168947","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T19:32:49Z","timestamp":1601321569000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0168947"}},"subtitle":[],"editor":[{"given":"Matthaios","family":"Speletas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0168947","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,3]]}}}